Clopidogrel is used for
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest clopidogrel is used for preventing vascular events, treating acute coronary syndromes, preventing stent thrombosis, reducing ischemic events in stroke or TIA patients, and as an antiplatelet therapy in cardiovascular diseases.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Clopidogrel: Uses and Clinical Applications
Clopidogrel for Atherosclerotic Event Reduction
Clopidogrel is an ADP receptor antagonist primarily used to reduce atherosclerotic events such as myocardial infarction, ischemic stroke, and vascular death in patients with atherosclerosis. This includes individuals with recent stroke, myocardial infarction, or established peripheral vascular disease. The CAPRIE study demonstrated that clopidogrel significantly lowers the annual risk of combined ischemic stroke, myocardial infarction, and vascular death compared to aspirin.
Dual Antiplatelet Therapy (DAPT) in Acute Coronary Syndromes (ACS)
Clopidogrel is often used in combination with aspirin as part of dual antiplatelet therapy (DAPT) for the treatment and secondary prevention of acute coronary syndromes (ACS). The CURE trial showed that clopidogrel combined with aspirin is more effective than aspirin alone in reducing cardiovascular death, non-fatal myocardial infarction, or stroke in patients with non-ST-segment elevation ACS. However, this combination is associated with a higher risk of bleeding.
Prevention of Stent Thrombosis
Clopidogrel is also used to prevent stent thrombosis in patients undergoing percutaneous coronary intervention (PCI). Studies have shown that clopidogrel, along with other P2Y12 inhibitors like prasugrel and ticagrelor, effectively reduces the risk of stent thrombosis. However, prasugrel may offer a lower complication rate compared to clopidogrel in certain neurointerventional procedures.
Clopidogrel in Stroke and Transient Ischemic Attack (TIA)
For patients with minor ischemic stroke or high-risk TIA, clopidogrel combined with aspirin is effective for secondary prevention. The CHANCE and POINT trials indicated that this combination reduces the risk of major ischemic events within the first 21 days of treatment. Clopidogrel monotherapy is also recommended for patients with symptomatic peripheral artery disease (PAD).
Clopidogrel in Cancer Treatment
Interestingly, clopidogrel has been studied for its potential anticancer and antimetastatic properties. While it enhances the efficacy of certain chemotherapeutics like 5-fluorouracil and cyclophosphamide, it may reduce the effectiveness of others such as doxorubicin and cisplatin. This dual nature necessitates careful evaluation when used in cancer patients undergoing chemotherapy.
Safety and Tolerability
Clopidogrel is generally well-tolerated, with a safety profile comparable to aspirin. It causes fewer gastrointestinal hemorrhages but may lead to more frequent occurrences of diarrhea, rash, and pruritus. When used in combination with other antiplatelet agents, the risk of bleeding increases, necessitating a careful balance of risks and benefits.
Conclusion
Clopidogrel is a versatile antiplatelet agent used in various clinical settings, including the prevention of atherosclerotic events, treatment of ACS, prevention of stent thrombosis, and secondary prevention in stroke and TIA. While it is effective and generally well-tolerated, its use in combination therapies, particularly with aspirin, requires careful management to mitigate the increased risk of bleeding. Additionally, its role in cancer treatment highlights the need for further research to fully understand its benefits and limitations in this context.
Sources and full results
Most relevant research papers on this topic
